Overview

The project has the scope to provide EU with a self sustainable and independent ability to discover, develop and manufacture vaccines and monoclonal antibodies against infectious diseases of epidemic and pandemic potential.

The EVH project contributes to the development of an agreed set of pandemic-prototype vaccines and scalable technologies through a consortium including leading EU organisations directly involved in vaccine development and in charge of pandemic preparedness in their own countries, ensuring effective coordination of national vaccine research programs. EVH aligns with the current international consensus on pandemic-vaccine development, leveraging insights from existing prototypes to enable the rapid selection and deployment of the most suitable vaccine candidates in an emerging pandemic.

From prototype design to clinical applications, the EVH drives innovation, enhances clinical evaluation capacities, and coordinate efforts with manufacturers while optimizing the digitalization of vaccine design and distribution processes. EVH aims thus not only to create a reactive R&D system and knowledge hub linking powerful leading research institutions, but also initiate vaccine-development projects, refining relevant processes and procedures within its framework. The focus is on a select group of pathogens deemed critical for pandemic preparedness.